ERBB2 and breast cancer: This translational study showed that IGF-1R expression changed in most of the tumors during treatment in stage II/III HER2-negative BC patients treated with neoadjuvant TAC chemotherapy and that absent or diminished expression after treatment was associated with a better pathological response according to MP classification.